clinical trial · NCT07347249
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
Congenital Factor VII DeficiencySutacimigSutacimig
brief summary
Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).
started
Jan 1, 2026
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
Jan 30, 2026
detailed description
The objective is to administer a single dose of sutacimig and to evaluate safety, pharmacokinetics, and pharmacodynamics. Two cohorts may be evaluated. Cohort A is defined by participants with a FVII(a) level of \< 10%. Cohort B is defined by participants with a FVII(a) level of ≥10%.
official title
A Clinical Study to Assess the Safety and Efficacy of Sutacimig in Participants With Congenital Factor VII Deficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol